1123. Deputy Ken O'Flynn asked the Minister for Health whether the HSE has a target timeline for completing reimbursement decisions in respect of orphan medicines or medicines for progressive rare diseases; and if no such target exists, whether one is under consideration. [32773/26]
Topics / Medicinal Products
A subject heading for parliamentary questionsMedicinal Products
1,233 questions from 132 TDs, between 22 January 2025 and 22 October 2026.
1,233
questions
1,229 written, 4 oral
132
TDs have asked
11
parties and groups
Independents counted together
4
departments asked
Questions per month
The record holds no questions for August, when the Dáil does not sit.
Jan 2025Oct 2026
Show as a table
| Month | Questions |
|---|---|
| January 2025 | 17 |
| February 2025 | 66 |
| March 2025 | 28 |
| April 2025 | 35 |
| May 2025 | 43 |
| June 2025 | 58 |
| July 2025 | 56 |
| August 2025 | 0 |
| September 2025 | 36 |
| October 2025 | 38 |
| November 2025 | 58 |
| December 2025 | 27 |
| January 2026 | 18 |
| February 2026 | 70 |
| March 2026 | 142 |
| April 2026 | 87 |
| May 2026 | 156 |
| June 2026 | 127 |
| July 2026 | 82 |
| August 2026 | 0 |
| September 2026 | 62 |
| October 2026 | 27 |
Who asks, by party
The party each TD belonged to on the day, in alphabetical order. Parties differ a lot in size, and members of the Government answer questions rather than ask them, so this shows who raised it, not how much a party cares about it.
The TDs who asked most
Members of the Government answer questions rather than ask them. Each question counts once.
-
196
-
75
-
43
-
42
-
39
-
26
-
26
-
26
Asked of
Debated under the same heading
Debates whose official heading is exactly these words.
The questions
1124. Deputy Ken O'Flynn asked the Minister for Health whether the HSE has any escalation process where a reimbursement application concerns a progressive neurological condition in which delay may lead to irreversible deterioration. [32774/26]
1125. Deputy Ken O'Flynn asked the Minister for Health whether the HSE has considered international reimbursement or access decisions in respect of omaveloxolone, marketed as Skyclarys, including decisions in France, Italy, Germany or other comparable European countries, as part of the Irish reimbursement process. [32775/26]
1126. Deputy Ken O'Flynn asked the Minister for Health whether the Department or HSE has examined the favourable reimbursement opinion issued in France for Skyclarys in Friedreich’s ataxia, and whether such international assessments are considered in Irish rare disease reimbursement decisions. [32776/26]
1127. Deputy Ken O'Flynn asked the Minister for Health whether the Department or HSE is aware that Italy’s medicines authority approved reimbursement of Skyclarys for Friedreich’s ataxia in December 2025, and whether this decision has been considered in the Irish process. [32777/26]
1128. Deputy Ken O'Flynn asked the Minister for Health whether the HSE has received a commercial proposal from Biogen Idec Ireland Limited in respect of omaveloxolone, marketed as Skyclarys, since 16 April 2026; and if not, what steps the HSE is taking to progress the matter. [32778/26]
1129. Deputy Ken O'Flynn asked the Minister for Health whether any statutory, contractual, policy or administrative time limits apply where a marketing authorisation holder has been invited to submit a commercial proposal for a medicine but has not yet done so. [32779/26]
1130. Deputy Ken O'Flynn asked the Minister for Health whether she will consider introducing a formal interim access pathway for rare disease medicines where a treatment has European marketing authorisation, there is no alternative disease-modifying therapy available, and the reimbursement process remains unresolved. [32780/26]
1133. Deputy Barry Heneghan asked the Minister for Health whether her Department has examined the practice of pharmacies charging additional fees for dispensing medications in blister packs where this is clinically required, particularly for older persons with complex medication regimes; whether any guidance or regulation exists governing such charges under the community drug schemes; if consideration is being given …
1134. Deputy Barry Ward asked the Minister for Health the position regarding any research being carried out into the viability of providing treatment for people suffering from Friedrichs ataxia in Ireland; and if she will make a statement on the matter. [32792/26]
1136. Deputy Barry Ward asked the Minister for Health the position regarding the approval process for skyclarys as a treatment for Friedrichs ataxia; and if she will make a statement on the matter. [32794/26]
1137. Deputy Barry Ward asked the Minister for Health her views on whether the delays in the approval of skyclarys as a treatment for Friedrichs ataxia aligns with the "equitable access" as outlined in the National Rare Disease Strategy 2025-2030; and if she will make a statement on the matter. [32795/26]
1157. Deputy Ken O'Flynn asked the Minister for Health whether her Department receives aggregated national reporting on waiting times for access to PrEP services; and if so, to provide the most recent data. [32892/26]
1158. Deputy Ken O'Flynn asked the Minister for Health whether a national register or centralised data system exists to track demand for PrEP services across all providers; and if not, whether one is planned. [32893/26]
1159. Deputy Ken O'Flynn asked the Minister for Health the total number of clinics currently delivering PrEP services nationally, including both public and private providers, and whether this number has increased since 2023. [32894/26]
1160. Deputy Ken O'Flynn asked the Minister for Health whether any national standard exists for maximum acceptable waiting times for access to PrEP services; and if not, whether such a standard will be introduced. [32895/26]
1161. Deputy Ken O'Flynn asked the Minister for Health whether her Department has assessed geographic disparities in access to PrEP services; and if so, to provide details of any identified gaps. [32896/26]
1162. Deputy Ken O'Flynn asked the Minister for Health the estimated number of individuals unable to access PrEP services due to capacity constraints in the most recent year. [32897/26]
1163. Deputy Ken O'Flynn asked the Minister for Health whether any interim or bridging access arrangements exist for individuals clinically eligible for PrEP but unable to secure an appointment within the public system. [32898/26]
1164. Deputy Ken O'Flynn asked the Minister for Health whether funding allocated to expand PrEP capacity in 2025 and 2026 has been fully utilised; and if not, the reasons for any underspend. [32899/26]
1173. Deputy Colm Burke asked the Minister for Health the steps planned to protect patients' safety in light of recent figures from the HPRA that show a major spike in the volume of illegally sourced obesity medicines detained last year. [32944/26]
1174. Deputy Colm Burke asked the Minister for Health the action she intends to take to protect patients from the health risks of the rapidly increasing availability of counterfeit obesity medicines which are untested, unregulated and unlicensed. [32945/26]
1182. Deputy Mark Wall asked the Minister for Health the steps she is taking to reduce the waiting time for patients to claim refunds for medication from the HSE raised by a person in Kildare south (details supplied); and if she will make a statement on the matter. [32970/26]
1190. Deputy Pádraig O'Sullivan asked the Minister for Health the average length of time taken by the HSE Drugs Group to issue a final reimbursement decision following receipt of a National Centre for Pharmacoeconomics Health Technology Assessment in each of the past five years; whether her Department has assessed the impact of these timelines on patients with rare diseases; and if she will make a statement on the ma…
1191. Deputy Pádraig O'Sullivan asked the Minister for Health whether her Department has considered introducing a managed access scheme or interim reimbursement pathway for orphan and rare disease medicines that have received European Medicines Agency authorisation but are awaiting a final HSE reimbursement decision; and if she will make a statement on the matter. [33126/26]